Back to results
US 12,606,616 B2Granted
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
AssigneeCardiff Oncology, Inc.
InventorsMaya Ridinger, Mark Erlander
Life of this patent
Estimating the term…
Abstract
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
Claims17
A method of treating a patient having a metastatic colorectal cancer, comprising:
- administering to the patient an effective amount of onvansertib and bevacizumab in combination with a chemotherapy containing fluorouracil,
- wherein the patient has not received any prior treatment for the metastatic colorectal cancer and has not received any prior treatment with bevacizumab, and
- wherein onvansertib is administered multiple doses and bevacizumab is administered multiple doses during a treatment cycle.
Dependencies are inferred from the claim text.